Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses step therapy and its impact on patients.
Transcript:
What is your organization’s position on step therapy?
So, step therapy is a topic that causes a lot of emotion from our community members—from people living with chronic disease. Most of our membership have experienced step-therapy at one point or another. We understand in concept why insurers use step therapy, [but] we think it’s like using a hatchet to attempt a surgery. It really is kind of a 1-size-fits-all practice that really isn’t applicable.
We think medicine is so nuanced, and especially the patients in our community live with very complex chronic diseases, [so] you cannot make a policy as encompassing as a step therapy, or like folks in our community like to call it, “fail first,” that is going to work for everyone.
We understand generally why it’s in place. We think it’s appropriate in some cases, but for the vast majority of the instances we think it’s very inappropriate, and we would argue even unethical.
I think that we’re encouraged to see many states across the country starting to implement legislation that has been introduced—a newer version of step-therapy legislation—that was introduced starting around 2015 that is much stronger than previous attempts that don’t look to just prohibit step-therapy, because we understand that that’s not reasonable. But it looks to put some guard rails in place or it looks to really protect the patient from the step therapy practices going too far.
If we look at New York, for instance, legislation was passed in our home state through the efforts of a very diverse coalition of many, many patient groups—I believe there were over 60 patient groups that worked together to get that bill passed. But that bill, what it specifically did and now does under law, it mandates that step therapy protocols are developed using clinical criteria and that that clinical criteria are really [coming from] a third party [such as] a professional society, [or] a professional college of medicine. It’s under the direction of medical information, not financial information.
Number 2, it sets out clear criteria for which a physician and their patient can use to appeal a step-therapy policy. One of the more critical parts of the legislation is that it puts in place a time requirement for which the insurer has to respond to that appeal.
So, in New York, that’s 72 hours, or in the case of an emergency [it’s] 24 hours. That’s a really important part, because when we go to state capitols across the country with other groups to advocate for this type of legislation, many times we hear from folks on the other side “well, we already have an appeals process in place.” But when you’ve seen 1 insurer’s appeals process, you’ve seen 1 insurer’s appeals process. There’s no uniformity. This drives physicians crazy, it drives patients crazy because people are changing their insurance plans from time to time and 1 of the largest complaints we hear is that I file an appeal, but just because I file an appeal doesn’t mean anything. We’ve heard patients wait up to 130 days before they get a response to an appeal.
It’s really critical that that protection be a part of the legislation, and so we’re working to pass that in many other states. I would direct folks to 1 of our websites, failfirsthurts.org, where we track a lot of this legislation and we list out many of these kinds of principles that I just spoke about.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.